PT - JOURNAL ARTICLE AU - Tan, Sophia T. AU - Rodríguez-Barraquer, Isabel AU - Kwan, Ada T. AU - Blumberg, Seth AU - Park, Hailey J. AU - Hutchinson, Justine AU - Leidner, David AU - Lewnard, Joseph A. AU - Sears, David AU - Lo, Nathan C. TI - Strength and durability of indirect protection against SARS-CoV-2 infection through vaccine and infection-acquired immunity AID - 10.1101/2024.07.23.24310889 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.23.24310889 4099 - http://medrxiv.org/content/early/2024/10/09/2024.07.23.24310889.short 4100 - http://medrxiv.org/content/early/2024/10/09/2024.07.23.24310889.full AB - Early investigation revealed that COVID-19 vaccines confer indirect protection to fully susceptible and unvaccinated persons, defined as a reduced risk of SARS-CoV-2 infection among social contacts of vaccinated individuals. However, indirect protection from infection-acquired immunity and its comparative strength and durability to vaccine-derived indirect protection in the current epidemiologic context of high levels of vaccination, prior infection, and novel variants are not well characterized. Here, we show that both infection-acquired and vaccine-derived immunity independently yield indirect protection to close social contacts with key differences in their strength and waning. Analyzing anonymized data from a system-wide SARS-CoV-2 surveillance program of 177,319 residents across 35 California state prisons from December 2021 to December 2022 in a case-control design, we find that vaccine-derived indirect protection against Omicron SARS-CoV-2 infection is strongest within three months post-vaccination [30% (95% confidence interval: 20-38%)] with subsequent modest protection, whereas infection-acquired immunity provides 38% (24-50%) indirect protection to roommates for 6 months after SARS-CoV-2 infection, with moderate indirect protection persisting for over one year. Variant-targeted vaccines (bivalent formulation including Omicron subvariants BA.4/BA.5) confer strong indirect protection for at least three months [40% (3-63%)]. These results have important implications for understanding the long-term transmission dynamics of SARS-CoV-2 and can guide vaccine policy and public health measures, especially in high-risk environments such as prisons.Competing Interest StatementJAL has received grants, honoraria, and speaker fees from Pfizer; grants and honoraria from Merck, Sharp, & Dohme; honoraria from Valneva; and honoraria from VaxCyte; all unrelated to the subject of this work. ATK and DS received funding from California Prison Health Care Receivership. NCL reports consulting fees from the World Health Organization related to guidelines on neglected tropical diseases, which are outside the scope of the present work. The remaining authors have no disclosures.Funding StatementNCL is supported by the National Institutes of Health, NIAID New Innovator Award (DP2AI170485)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the IRB at Stanford University and UCSF. The IRB included a waiver of consent given use of retrospective secondary data without direct identifiers that were collected for public health surveillance and deemed to be minimal risk.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData requests may be made to California Correctional Health Care Services and are subject to controlled access. All analytic code is publicly available at https://github.com/sophttan/covid-indirects.